{
    "root": "1908b5d2-6795-4a9b-b04b-1443ac2a7aa7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Kimyrsa",
    "value": "20250429",
    "ingredients": [
        {
            "name": "ORITAVANCIN DIPHOSPHATE",
            "code": "VL1P93MKZN"
        },
        {
            "name": "HYDROXYPROPYL BETADEX",
            "code": "1I96OHX6EK"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "PHOSPHORIC ACID",
            "code": "E4GA8884NN"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "kimyrsa lipoglycopeptide antibacterial indicated treatment adult patients acute bacterial skin skin structure infections caused suspected caused susceptible isolates designated gram-positive microorganisms . ( 1.1 ) reduce development drug-resistant bacteria maintain effectiveness kimyrsa antibacterial drugs , kimyrsa used treat prevent infections proven strongly suspected caused bacteria . ( 1.2 )",
    "contraindications": "two oritavancin products ( kimyrsa orbactiv ® , another oritavancin product ) differences dose strength , duration infusion preparation instructions , including reconstitution dilution instructions compatible diluents ( 2.1 , 2.2 , 2.3 , 2.4 ) administer 1,200 mg kimyrsa single dose intravenous infusion 1 hour . ( 2.1 , 5.3 ) carefully follow recommended dose preparation instructions kimyrsa full prescribing information . ( 2.1 , 2.2 , 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "intravenous unfractionated heparin sodium contraindicated 120 hours ( 5 days ) kimyrsa . ( 4.1 , 5.1 ) known hypersensitivity oritavancin products . ( 4.2 , 5.2 )",
    "indications_original": "KIMYRSA is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of KIMYRSA and other antibacterial drugs, KIMYRSA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 )",
    "contraindications_original": "There are two oritavancin products (KIMYRSA and ORBACTIV ® , another oritavancin product) that have differences in dose strength, duration of infusion and preparation instructions, including reconstitution and dilution instructions and compatible diluents ( 2.1 , 2.2 , 2.3 , 2.4 ) Administer 1,200 mg of KIMYRSA as a single dose by intravenous infusion over 1 hour. ( 2.1 , 5.3 ) Carefully follow the recommended dosage and dose preparation instructions for KIMYRSA in the full prescribing information. ( 2.1 , 2.2 , 2.3 )",
    "adverseReactions_original": "Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA administration. ( 4.1 , 5.1 ) Known hypersensitivity to oritavancin products. ( 4.2 , 5.2 )"
}